

**Virginia Medicaid**  
**Pharmacy & Therapeutics Committee Meeting**  
Agenda  
600 East Broad Street – 1st Floor Conference Rooms  
Richmond, VA 23219  
Thursday, March 21, 2024 – 10 AM

Welcome and Comments Cheryl J. Roberts, J.D. Medicaid Director

Call to Order Lisa Price Stevens, MD, Chief Medical Officer, Chair

Drug Utilization Review (DUR) Board Report Rachel Cain, PharmD

Approval of Minutes from September 21, 2023, and October 18<sup>th</sup>, 2023 Meetings P&T Committee Members

Old Business P&T Committee Members

- Bylaws
- P&T committee members reminder to sign and return conflict of interest document

PDL (PREFERRED DRUG LIST) Management P&T Committee Members

PDL Phase I – New Drug Review (*Therapeutic Class*)

**Brand Drugs**

- Motpoly XR *(Anticonvulsants) (Closed Class)*
- Zurzuvae™ *(Antidepressants, Other)*
- Rykindo™ *(Antipsychotics, Long Acting) (Closed Class)*
- Ngenla™ *(Growth Hormone) (Closed Class)*
- Iyuzeh™ *(Ophthalmics, Glaucoma Agents)*
- Xphozah™ *(Phosphate Binders)*
- Zepbound™ *(Weight Management Agents) (Closed Class)*

**Generics Drugs or New Dosage Forms**

- tiotropium *(COPD Agents) (Closed Class)*
- fluticasone prop diskus & breyna *(Glucocorticoids, Inhaled) (Closed Class)*
- pitavastatin calcium *(Lipotropics, Statins)*

**Potential New PDL Closed Classes**

- Immunomodulators, Asthma *(Potential New PDL Closed Class)*

PDL Phase II – Annual Review: Classes with updates

**Analgesics**

- Antimigraine Agents Other *(Closed Class)*
- Non-Steroidal Anti-Inflammatory Drugs (NSAID) (includes Cox-2 inhibitors and topical agents)
- Opioids: Short Acting (includes combination drugs and lozenges)
- Opioid Dependency Treatment Agents *(Closed Class)* (includes oral buprenorphine)

**Antibiotics / Anti-Infectives**

- Gastrointestinal

**Blood Modifiers**

- Erythropoiesis Stimulating Proteins

**Central Nervous System**

- Antihyperkinesia/CNS Stimulants (Closed Class)

**Dermatologic Agents (Topical)**

- Acne Agents (includes benzoyl peroxide, clindamycin, retinoids & combinations)

**Endocrine and Metabolic Agents**

- Hypoglycemics: Incretin- Mimetics- Exenatide (includes DPPIV & combination) (Closed Class)
- Hypoglycemics: Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor (Closed Class)

**Immunological Agents**

- Self-administered Cytokine & CAM Antagonists with Related Agents including Methotrexate (*all indications: Rheumatoid Arthritis (RA), Juvenile Idiopathic Arthritis (JIA), Ankylosing Spondylitis (AS), Plaque Psoriasis, Psoriatic Arthritis (PsA), Crohn's Disease (CD), Ulcerative Colitis, Cryopyrin-Associated Periodic Syndromes (CAPS)*) (Closed Class)

**PDL Phase II – Annual Review**

**Therapeutic Classes without Significant Updates (reviewed by the Department)**

**Analgesics**

- Antimigraine Agents
- Opioids: Long Acting

**Antibiotics / Anti-Infectives**

- Antifungal (oral)
- Antibiotics (topical)
- Cephalosporins (Second and Third Generations)
- Ketolides & Macrolides (Adult and Pediatric)
- Quinolones (Second and Third Generations)
- Quinolones (Otic)

**Antivirals**

- Antivirals for Herpes (HSV)
- Antivirals for Influenza

**Blood Modifiers**

- Antihyperuricemics

**Cardiac**

- Anticoagulants (*includes oral agents, low molecular weight heparins & Factor XA Inhibitors*) (Closed Class)
- Platelet Aggregation Inhibitors

**Central Nervous System**

- Alzheimer's Agents (Cholinesterase Inhibitors & NMDA Receptor Antagonist)
- Multiple Sclerosis Agents (Closed Class)
- Neuropathic Pain
- Skeletal Muscle Relaxants
- Smoking Cessation Agents

**Contraceptives**

- Long-Acting Reversible Contraceptives (LARCS) (includes long-acting IUDs & injectable)

**Dermatologic Agents (Topical)**

- Antifungal Agents, Topical
- Psoriasis Agents
- Rosacea Agents

**Endocrine and Metabolic Agents**

- Androgenic Agents
- Bone Resorption Suppression and Related Agents (includes bisphosphonates, calcitonin, and others)
- Estrogens (vaginal)
- Hypoglycemics: Alpha-Glucosidase Inhibitors
- Hypoglycemics: Insulins
- Hypoglycemics: Meglitinides
- Hypoglycemics: Metformin
- Hypoglycemics: Sulfonylureas
- Hypoglycemics: Thiazolidinediones
- Pancreatic Enzymes
- Progestational Agent (Closed Class)

**Confidential Meeting (Pricing Information Discussion)**

**P&T Committee Members & DMAS Staff**

**Criteria Discussion of Phase I New Drugs**

**P&T Committee Members**

**Criteria Discussion of Phase II Drugs**

**P&T Committee Members**

*\*Criteria discussions will be held for classes only if deemed PDL eligible by the P&T Committee during Drug Class Discussions.*

**Other Business**

**Chair**

**Next Meeting – June 27, 2024 (tentative)**

**Chair**

**Oral Presentations:** The P&T Committee in conjunction with the Department will be allocating time slots for interested parties to present scientific and clinical information on **only** the drug classes in Phase II scheduled for review at the March meeting and new drugs in PDL Phase I listed on the Agenda. **All presentations must include information published in a peer reviewed journal (per guidelines below) that is clinical in nature and based on scientific material. The references used to authorize presentations must be within the following timeframes:**

- PDL Phase II Annual Reviews – March 2023 to present.
- New Drugs in PDL Phase I or II Drug Classes – March 2022 to present.
- Potential new drug classes – March 2022 to present.

No anecdotal accounts are to be given. Each speaker will be allocated no more than 2 minutes to present. Speakers will be decided by the Chairperson based on relevancy of the information. **Speakers must receive a confirmation to verify the presentation is scheduled.**

**Anyone interested in providing specific clinical information to the Committee at the meeting must submit an outline of discussion points, clinical references (within the stated guidelines above) and a written request to speak with the name/title of the presenter. Please send requested information to [pdlinput@dmas.virginia.gov](mailto:pdlinput@dmas.virginia.gov) [dfmoody@magellanhealth.com](mailto:dfmoody@magellanhealth.com) and [debbie.moody@primetherapeutics.com](mailto:debbie.moody@primetherapeutics.com) by 5 p.m. EST on Friday, February 23, 2024.**

**Written information/comments:** The P&T Committee will also accept written comments for consideration. Please send statements to [pdlinput@dmas.virginia.gov](mailto:pdlinput@dmas.virginia.gov) by 5 p.m. EST Friday, February 23, 2024. **The Potential new class Immunomodulators, Asthma has an extension of 1 week and are due by Friday March 1<sup>st</sup> 2024.**